1.Decompression Retinopathy after Trabeculectomy.
Korean Journal of Ophthalmology 2005;19(2):128-131
PURPOSE: To present a case of a unilateral diffuse retinal hemorrhage in a 15-year-old girl, who underwent bilateral trabeculectomy for steroid induced glaucoma. METHODS: Despite the maximally tolerable medical treatment, IOP in the right eye remained above 50 mmHg for four months, and was simultaneously elevated in the left eye. So we performed bilateral trabeculectomy. RESULTS: On the first postoperative day, diffuse retinal hemorrhages were observed in the right eye; however, no retinal hemorrhage was found in the left eye. The hemorrhages resolved completely without consequences two months later. CONCLUSIONS: In the case of high IOP for a long period, sudden lowering of IOP may acutely increase the blood flow and consequently rupture multiple retinal capillaries because of altered autoregulatory function. Special care is therefore needed to prevent an abrupt fall in IOP before, during, and after surgery, especially when IOP has been highly elevated for an extended period.
Administration, Topical
;
Adolescent
;
Female
;
Fluorescein Angiography
;
Fundus Oculi
;
Glaucoma/chemically induced/*surgery
;
Humans
;
Retinal Hemorrhage/diagnosis/*etiology/pathology
;
Steroids/administration & dosage/adverse effects/therapeutic use
;
Trabeculectomy/*adverse effects
;
Uveitis/drug therapy
2.A Case of Ischemic Skin Necrosis after Glypressin Therapy in Liver Cirrhosis.
Ji Eun OH ; Jung Soo HA ; Dae Hyeon CHO ; Gil Jong YU ; Sang Goon SHIM
The Korean Journal of Gastroenterology 2008;51(6):381-384
Terlipressin is a synthetic analogue of vasopressin, which has been used in the treatment of acute variceal hemorrhage. In contrast to vasopressin, terlipressin can be administered as intermittent injections instead of continuous intravenous infusion. Thus, it has a less adverse reaction than vasopressin. We report a case of ischemic skin complication in a cirrhotic patient treated with terlipressin. A 71-year-old man with liver cirrhosis was admitted because of hematemesis and melena. He was commenced on terlipressin at a dose 1 mg every 6 hours for the treatment of varicieal bleeding. After 36 hours of treatment, skin blistering and ecchymosis was noted on the skin of his upper thigh, scrotal area and trunk. We found that terlipressin was a possible cause of ischemic skin complication based on the skin biopsy finding. Terlipressin may induce a complication of the ischemic event. In spite of rarity, special attention needs to paid on the peripheral ischemic complication of terlipressin.
Aged
;
Fatal Outcome
;
Hematemesis/diagnosis
;
Hemorrhage/drug therapy
;
Humans
;
Ischemia/*chemically induced/*pathology
;
Liver Cirrhosis/*complications
;
Lysine Vasopressin/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use
;
Male
;
Melena/diagnosis
;
Necrosis
;
Skin/*blood supply/drug effects/*pathology
;
Vasoconstrictor Agents/administration & dosage/*adverse effects/therapeutic use
3.Evaluation of CRUSADE and ACUITY-HORIZONS Scores for Predicting Long-term Out-of-Hospital Bleeding after Percutaneous Coronary Interventions.
Xue-Yan ZHAO ; Jian-Xin LI ; Xiao-Fang TANG ; Ying XIAN ; Jing-Jing XU ; Ying SONG ; Lin JIANG ; Lian-Jun XU ; Jue CHEN ; Yin ZHANG ; Lei SONG ; Li-Jian GAO ; Zhan GAO ; Jun ZHANG ; Yuan WU ; Shu-Bin QIAO ; Yue-Jin YANG ; Run-Lin GAO ; Bo XU ; Jin-Qing YUAN
Chinese Medical Journal 2018;131(3):262-267
BACKGROUND:
There is scanty evidence concerning the ability of Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) and Acute Catheterization and Urgent Intervention Triage Strategy and Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (ACUITY-HORIZONS) scores to predict out-of-hospital bleeding risk after percutaneous coronary interventions (PCIs) with drug-eluting stents (DES) in patients receiving dual antiplatelet therapy. We aimed to assess and compare the long-term prognostic value of these scores regarding out-of-hospital bleeding risk in such patients.
METHODS:
We performed a prospective observational study of 10,724 patients undergoing PCI between January and December 2013 in Fuwai Hospital, China. All patients were followed up for 2 years and evaluated through the Fuwai Hospital Follow-up Center. Major bleeding was defined as Types 2, 3, and 5 according to Bleeding Academic Research Consortium Definition criteria.
RESULTS:
During a 2-year follow-up, 245 of 9782 patients (2.5%) had major bleeding (MB). CRUSADE (21.00 [12.00, 29.75] vs. 18.00 [11.00, 26.00], P < 0.001) and ACUITY-HORIZONS (9.00 [3.00, 14.00] vs. 6.00 [3.00, 12.00], P < 0.001) risk scores were both significantly higher in the MB than non-MB groups. Both scores showed a moderate predictive value for MB in the whole study cohort (area under the receiver-operating characteristics curve [AUROC], 0.565; 95% confidence interval [CI], 0.529-0.601, P = 0.001; AUROC, 0.566; 95% CI, 0.529-0.603, P < 0.001, respectively) and in the acute coronary syndrome (ACS) subgroup (AUROC: 0.579, 95% CI: 0.531-0.627, P = 0.001; AUROC, 0.591; 95% CI, 0.544-0.638, P < 0.001, respectively). However, neither score was a significant predictor in the non-ACS subgroup (P > 0.05). The value of CRUSADE and ACUITY-HORIZONS scores did not differ significantly (P > 0.05) in the whole cohort, ACS subgroup, or non-ACS subgroup.
CONCLUSIONS
CRUSADE and ACUITY-HORIZONS scores showed statistically significant but relatively limited long-term prognostic value for out-of-hospital MB after PCI with DES in a cohort of Chinese patients. The value of CRUSADE and ACUITY-HORIZONS scores did not differ significantly (P > 0.05) in the whole cohort, ACS subgroup, or non-ACS subgroup.
Acute Coronary Syndrome
;
therapy
;
Aged
;
Angina, Unstable
;
therapy
;
Drug-Eluting Stents
;
Female
;
Humans
;
Male
;
Middle Aged
;
Myocardial Infarction
;
therapy
;
Percutaneous Coronary Intervention
;
Platelet Aggregation Inhibitors
;
adverse effects
;
Postoperative Hemorrhage
;
chemically induced
;
diagnosis
;
epidemiology
;
surgery
;
Practice Guidelines as Topic
;
Prognosis
;
Prospective Studies
;
Research Design
;
Risk
;
Risk Assessment
;
Treatment Outcome
4.Korean Patients with Superwarfarin Intoxication and Their Outcome.
Junshik HONG ; Ho Young YHIM ; Soo Mee BANG ; Sung Hwa BAE ; Young Jin YUH ; Sung Soo YOON ; Hwi Joong YOON ; Seung Taik KIM ; Hyun Sook CHI
Journal of Korean Medical Science 2010;25(12):1754-1758
This observational study aimed at evaluating recent superwarfarin intoxication of Korean patients. Ten patients were diagnosed as or highly suspicious for superwarfarin intoxication. Case report forms described by attending hematologists of the patients were collected and analyzed. Bleeding symptoms were varied among the patients. Patients uniformly showed prolonged prothrombin time (PT) and activated thromboplastin time (aPTT) with decreased activity of vitamin K dependent coagulation factors. Positive serum brodifacoum test results in 4 of 5 requested patients contributed to confirmatory diagnosis. Psychiatric interview revealed an attempted ingestion in one patient. High dose vitamin K1 therapy promptly corrected prolonged PT and aPTT, but hasty discontinuation caused repeated bleeding diathesis in 6 patients. Route of intoxication was unknown or not definite among 8 of 10 patients. Three patients had a possibility of environmental exposure considering their occupations: there might be intoxication by transdermal absorption or inhalation. Therefore, high dose and prolonged use of vitamin K1 therapy is necessary for effective detoxification. Further detailed investigation on environmental exposure and efforts to improve availability of the blood level test in clinic are requested.
4-Hydroxycoumarins/*poisoning
;
Adult
;
Aged
;
Aged, 80 and over
;
Anticoagulants/*poisoning
;
Antifibrinolytic Agents/therapeutic use
;
Environmental Exposure
;
Female
;
Hemorrhage/*chemically induced/diagnosis/drug therapy
;
Humans
;
Male
;
Middle Aged
;
Partial Thromboplastin Time
;
Prothrombin Time
;
Republic of Korea
;
Treatment Outcome
;
Vitamin K 1/therapeutic use
5.Clinical Impact of Dual Antiplatelet Therapy on Peptic Ulcer Disease.
Dae Geon AHN ; Beom Jin KIM ; Jeong Wook KIM ; Jae Gyu KIM
The Korean Journal of Gastroenterology 2014;64(2):81-86
BACKGROUND/AIMS: Increased incidence of coronary artery disease has led to the increased use of dual antiplatelet therapy composed of aspirin and clopidogrel. We investigated the incidence of gastrointestinal complications in patients who received single or dual antiplatelet therapy and analyzed their clinical characteristics in order to predict the prognostic factors. METHODS: Between January 2009 and December 2011, we retrospectively reviewed the medical records of patients who underwent coronary angiography at Chung-Ang University Hospital (Seoul, Korea). One hundred and ninety-four patients were classified into two groups: aspirin alone group and dual antiplatelet group. Clinical characteristics, past medical history, and presence of peptic ulcer were analyzed. RESULTS: During the follow-up period, 11 patients had duodenal ulcer; the event rate was 2.02% in the aspirin alone group and 9.47% in the dual antiplatelet group (hazard ratio [HR] 5.24, 95% CI 1.03-26.55, p<0.05). There was no significant difference in the rate of significant upper gastrointestinal bleeding: 0% vs. 4.2% (p=0.78). In patients who received proton pump inhibitor (PPI), 24 patients had gastric ulcer; the event rate was significantly different between the two groups: 4.87% vs. 22.98% (HR 3.40, 95% CI 1.02-11.27, p<0.05). CONCLUSIONS: Dual antiplatelet groups had a higher incidence of duodenal ulcers without significant bleeding compared with the aspirin alone group. In patients who received PPI, the dual antiplatelet therapy group had a higher incidence of gastric ulcers without significant bleeding compared with the aspirin alone group. Therefore, physicians must pay attention to high risk groups who receive dual antiplatelet therapy and aggressive diagnostic endoscopy should also be considered.
Aged
;
Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use/toxicity
;
Aspirin/*therapeutic use/toxicity
;
Coronary Angiography
;
Coronary Artery Disease/*prevention & control
;
Drug Therapy, Combination
;
Female
;
Gastrointestinal Hemorrhage/chemically induced/prevention & control
;
Humans
;
Incidence
;
Male
;
Middle Aged
;
Peptic Ulcer/*diagnosis/epidemiology/etiology
;
Platelet Aggregation Inhibitors/*therapeutic use/toxicity
;
Proportional Hazards Models
;
Proton Pump Inhibitors/therapeutic use
;
Retrospective Studies
;
Risk Factors
;
Ticlopidine/*analogs & derivatives/therapeutic use/toxicity
6.A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome.
Ji Hyun LEE ; Sung Gyun AHN ; Bonil PARK ; Sang Wook PARK ; Yong Seok KANG ; Jun Won LEE ; Young Jin YOUN ; Min Soo AHN ; Jang Young KIM ; Byung Su YOO ; Seung Hwan LEE ; Junghan YOON
The Korean Journal of Internal Medicine 2015;30(5):620-628
BACKGROUND/AIMS: Newer P2Y12 inhibitors, such as prasugrel and ticagrelor, have greater antiplatelet efficacy but may increase the risk of bleeding. In this study, we compared the pharmacodynamic efficacy of prasugrel and ticagrelor in East Asian patients with acute coronary syndrome (ACS). METHODS: We selected 83 ACS patients undergoing percutaneous coronary intervention who were discharged with 90 mg ticagrelor twice daily (n = 24), 10 mg prasugrel daily (n = 39) or 5 mg prasugrel daily (n = 20). After 2 to 4 weeks, on-treatment platelet reactivity (OPR) was assessed in terms of P2Y12 reaction units (PRUs) using the VerifyNow P2Y12 assay (Accumetrics). We compared East Asian (85 < PRU < or = 275) and Caucasian (85 < PRU < or = 208) criteria for assessing the therapeutic window of OPR. RESULTS: OPR was lowest in the ticagrelor group, followed by the 10 mg prasugrel and 5 mg prasugrel groups (49.1 ± 29.9 vs. 83.7 ± 57.1 vs. 168.5 ± 60.8, respectively; p < 0.001). The 5 mg prasugrel group had the highest proportion of patients with OPR values within the therapeutic window, followed by the 10 mg prasugrel and ticagrelor groups (90.0% vs. 46.2% vs. 12.5%, respectively; p < 0.001 for East Asian criteria; 60.0% vs. 43.6% vs. 12.5%, respectively; p < 0.001 for Caucasian criteria). CONCLUSIONS: Short-term administration of 5 mg prasugrel facilitated maintenance within the therapeutic window of OPR compared with the 10 mg prasugrel and ticagrelor groups. Thus, 5 mg prasugrel daily may be the optimal antiplatelet regimen for stabilized East Asian ACS patients.
Acute Coronary Syndrome/blood/diagnosis/ethnology/*therapy
;
Adenosine/administration & dosage/adverse effects/*analogs & derivatives/pharmacology
;
Aged
;
*Asian Continental Ancestry Group
;
Blood Platelets/*drug effects/metabolism
;
Drug Administration Schedule
;
Drug Monitoring/methods
;
European Continental Ancestry Group
;
Female
;
Hemorrhage/chemically induced
;
Humans
;
Male
;
Middle Aged
;
*Percutaneous Coronary Intervention/adverse effects
;
Pilot Projects
;
Platelet Aggregation Inhibitors/administration & dosage/adverse effects
;
Platelet Function Tests
;
Prasugrel Hydrochloride/administration & dosage/adverse effects/*pharmacology
;
Purinergic P2Y Receptor Antagonists/administration & dosage/adverse effects/*pharmacology
;
Receptors, Purinergic P2Y12/blood/*drug effects
;
Republic of Korea
;
Retrospective Studies
;
Risk Factors
;
Time Factors
;
Treatment Outcome